UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD

The journal of clinical endocrinology and metabolism, 2022-01, Vol.107 (1), p.29-38

2022

Volltextzugriff (PDF)

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Nature reviews. Gastroenterology & hepatology, 2021-01, Vol.18 (1), p.24-39

2021

Volltextzugriff (PDF)

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

Journal of hepatology, 2020-04, Vol.72 (4), p.613-626

2020

Volltextzugriff (PDF)

A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now

The journal of clinical endocrinology and metabolism, 2022-06, Vol.107 (7), p.e3076-e3077

Cusi, Kenneth

2022

Volltextzugriff (PDF)

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study

Hepatology communications, 2021-06, Vol.5 (6), p.938-946

2021

Volltextzugriff (PDF)

Letter to the Editor: “Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content

The journal of clinical endocrinology and metabolism, 2019-11, Vol.104 (11), p.5249-5250

2019

Volltextzugriff (PDF)

Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187-192

Diabetes care, 2018-09, Vol.41 (9), p.e137-e138

2018

Volltextzugriff (PDF)

Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit

Hepatology (Baltimore, Md.), 2017-07, Vol.66 (1), p.296-297

2017

Volltextzugriff (PDF)

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis

Journal of hepatology, 2020-03, Vol.72 (3), p.401-410

2020

Volltextzugriff (PDF)

Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence

Diabetes, obesity & metabolism, 2023-04, Vol.25 (4), p.1112-1116

2023

Volltextzugriff (PDF)

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Diabetes care, 2021-02, Vol.44 (2), p.399-406

2021

Volltextzugriff (PDF)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

Liver international, 2021-11, Vol.41 (11), p.2659-2670

2021

Volltextzugriff (PDF)

Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesityand Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2019-08, Vol.104 (8), p.3327

2019

Volltextzugriff (PDF)

759-P: Changes in Liver Fat in Patients with Type 2 Diabetes by Presence of Genetic Hepatic Steatosis in the SURPASS-3 MRI Substudy

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Management of NAFLD in primary care settings

Liver international, 2022-11, Vol.42 (11), p.2377-2389

2022

Volltextzugriff (PDF)

Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry

Diabetes care, 2023-12, Vol.46 (12), p.2162-2170

2023

Volltextzugriff (PDF)

Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients

Diabetes care, 2018-01, Vol.41 (1), p.187-192

2018

Volltextzugriff (PDF)

Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD

The journal of clinical endocrinology and metabolism, 2023-05, Vol.108 (5), p.1192-1201

2023

Volltextzugriff (PDF)

Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes

Obesity (Silver Spring, Md.), 2022-06, Vol.30 (6), p.1231-1238

2022

Volltextzugriff (PDF)

1342-P: Are Plasma Aminotransferases of Value in Screening Patients with T2DM for NAFLD or Fibrosis?

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

1284-P: Prediabetes with Obesity Is a Major Risk Factor for NAFLD and Liver Fibrosis

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

1338-P: Characteristics of Patients with Type 2 Diabetes without Nonalcoholic Fatty Liver Disease (NAFLD)

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

1339-P: Hepatic Steatosis and Fibrosis Are Common in Obese Patients with Type 2 Diabetes Mellitus (T2DM)

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

233-LB: Spinal Cord Injury Inhibited-FGF21 Signaling Is Associated with Dysregulation of Metabolic Gene Expression in Mouse Liver and Adipose Tissue

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

1346-P: Obesity and Type 2 Diabetes in Patients with NAFLD Are Independently Associated with the Risk of Liver Fibrosis, Insulin Resistance, and Atherogenic Dyslipidemia

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

ThemaFemale

ThemaLiver

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study

Letter to the Editor: “Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content

Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187-192

Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis

Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesityand Type 2 Diabetes

759-P: Changes in Liver Fat in Patients with Type 2 Diabetes by Presence of Genetic Hepatic Steatosis in the SURPASS-3 MRI Substudy

Management of NAFLD in primary care settings

Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry

Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients

Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD

Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes

1342-P: Are Plasma Aminotransferases of Value in Screening Patients with T2DM for NAFLD or Fibrosis?

1284-P: Prediabetes with Obesity Is a Major Risk Factor for NAFLD and Liver Fibrosis

1338-P: Characteristics of Patients with Type 2 Diabetes without Nonalcoholic Fatty Liver Disease (NAFLD)

1339-P: Hepatic Steatosis and Fibrosis Are Common in Obese Patients with Type 2 Diabetes Mellitus (T2DM)

233-LB: Spinal Cord Injury Inhibited-FGF21 Signaling Is Associated with Dysregulation of Metabolic Gene Expression in Mouse Liver and Adipose Tissue

1346-P: Obesity and Type 2 Diabetes in Patients with NAFLD Are Independently Associated with the Risk of Liver Fibrosis, Insulin Resistance, and Atherogenic Dyslipidemia

Aktive Filter

Suchergebnisse filtern